Peer reviewed

Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results.

Moel M, Harinath G, Lee V, et al. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging (Albany NY). 2025;17(4):908-936. doi:10.18632/aging.206235. PMID 40188830; PMCID PMC12074816.

National Library of MedicinePublished 2025Accessed 2026-07-12

Open original source

Registry record

Source metadata

Publisher: National Library of Medicine
Source type: Peer reviewed
Registry ID: research-rapa-05
DOI: 10.18632/aging.206235
PMID: 40188830
Source code: RAPA-05

Source usage

Linked from 1 page

Compound

Rapamycin (sirolimus)

Interpretation boundary

What this record can and cannot establish

Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.